| What is RSS feed? | About Us |
 |
 Search Score: 7/10
Source: news.yahoo.com --- 3 days ago
For dog owners, a diagnosis of lymphoma in their pet has been a death sentence. North Carolina State University hopes to change that. ...
Source: news.google.com --- 15 days ago
Amgen's Bone-Marrow Stimulator Wall Street Journal - 28 minutes ago By DAVID J. REYNOLDS The Food and Drug Administration on Friday approved Amgen Inc.'s Nplate, a product used to treat patients with a rare blood disorder. Amgen's Nplate Approved by US for Bleeding Disorder (Update3) Bloomberg Bone Marrow Treatment Approved for Rare Bleeding Disorder Washington Post MarketWatch - BusinessWeek - Reuters - RTT News all 42 news articles ... Source: news.bbc.co.uk --- 17 days ago
A journalist who campaigned to raise awareness of Bone Marrow donation dies from leukaemia at the age of 26. ... Source: www.ncbi.nlm.nih.gov --- 4 days ago
Related Articles Aging and lung injury repair: A role for Bone Marrow derived mesenchymal stem cells. J Cell Biochem. 2008 Aug 29; Authors: Mora AL, Rojas M The incidence of lung fibrosis increases with age. Aging is associated with modifications in the intracellular and extracellular environment including alteration of the extracellular matrix, imbalance of the redox state, accumulation of senescent cells and potential alteration of the recruitment of Bone Marrow mesenchymal stem cells. The combination of these senescence-related alterations in the lung and in Bone Marrow progenitor cells might be responsible of the higher susceptibility to lung fibrosis in elderly individuals. The understanding of these age related changes must be considered in the rationale for the development of therapeutic interventions to control lung injury and fibrosis. J. Cell. Biochem. (c) 2008 Wiley-Liss, Inc. PMID: 18759327 [PubMed - as supplied by publisher] ... Source: www.ncbi.nlm.nih.gov --- 3 days ago
Related Articles Adalimumab-induced noncaseating granuloma in the Bone Marrow of a patient being treated for rheumatoid arthritis. Rheumatol Int. 2008 Sep 2; Authors: Metyas SK, Tadros RM, Arkfeld DG Sarcoidosis is a multisystemic disease characterized by noncaseating granulomatous infiltration, primarily of the lungs and lymphatic system. While reports of the efficacy of adalimumab in the treatment of refractory sarcoidosis have been mixed, the more widely used infliximab has demonstrated clear efficacy in this disease. The association between tumor necrosis factor (TNF)-inhibitors and noncaseating granulomas in the lung has been reported in literature. With the exception of one patient treated with adalimumab, who developed pulmonary granuloma, the remaining patients described in literature were treated with etanercept. The current case study is, to our knowledge, the first to describe adalimumab-induced noncaseating granulomas in the Bone Marrow of a patient being treated for rheumatoid arthritis and suggests that although TNF-inhibitors are used in the treatment of granulomatous disorders, their use should be carefully monitored as, in rare cases, TNF-inhibitors may leave sufficient cytokine activation to support granuloma formation. PMID: 18762943 [PubMed - as supplied by publisher] ... Source: www.ncbi.nlm.nih.gov --- 3 hours ago
TRAIL promotes migration of human Bone Marrow multipotent stromal cells. Stem Cells. 2008 Sep 4; Authors: Secchiero P, Melloni E, Corallini F, Beltrami AP, Alviano F, Milani D, D'Aurizio F, di Iasio MG, Cesselli D, Bagnara GP, Zauli G Adult multipotent stromal cells (MSCs), also known as mesenchymal stem cells, represent an important source of cells for the repair of a number of damaged tissues. Both Bone Marrow (BM)-derived and amniotic MSCs expressed detectable surface levels of two (TRAIL-R2 and TRAIL-R4) out of four transmembrane TRAIL receptors. Although the best-characterized activity of TRAIL-R2 is the transduction of apoptotic signals, neither recombinant TRAIL (rTRAIL) nor infection with an adenovirus expressing TRAIL (Ad-TRAIL) induced cytotoxic effects on MSCs. Moreover, while rTRAIL did not affect proliferation or differentiation of MSCs along the osteogenic and adipogenic lineages, it significantly promoted the migration of human MSCs in range of concentrations comparable to that of soluble TRAIL in human plasma (100 pg/ml). Since rTRAIL induced the rapid phosphorylation of ERK1/2 in MSC cultures, and pretreatment with pharmacological inhibitors of the ERK1/2 pathway efficiently counteracted the rTRAIL-induced human MSC migration, these data indicate that ERK1/2 is involved in mediating the ability of rTRAIL to stimulate MSC migration. Taking into consideration that the soluble factors able to induce MSC migration have not ... Source: www.ncbi.nlm.nih.gov --- 1 day ago
25 new PubMed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Bone Marrow Transplantation These PubMed results were generated on 2008/09/05 PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. ... Source: www.ncbi.nlm.nih.gov --- 3 days ago
Related Articles Osteogenic differentiation of rat mesenchymal stem cells from adipose tissue in comparison with Bone Marrow mesenchymal stem cells: melatonin as a differentiation factor. Iran Biomed J. 2008 Jul;12(3):133-41 Authors: Zaminy A, Ragerdi Kashani I, Barbarestani M, Hedayatpour A, Mahmoudi R, Farzaneh Nejad A Background: Adipose-derived stem cells (ADSC) could be an appealing alternative to Bone Marrow stem cells (BMSC) for engineering cell-based osteoinductive grafts. Meanwhile, prior studies have demonstrated that melatonin can stimulate osteogenic differentiation. Therefore, we assayed and compared the melatonin effect on osteogenic differentiation of BMSC with that of ADSC. Methods: Mesenchymal stem cells (MSC) were isolated from the Bone Marrow and fat of adult rats. Both cell types were cultured in osteogenic medium in the absence and presence of melatonin at physiological concentrations (20-200 pg/ml). After 4 weeks, the expression of osteocalcin gene was analyzed by reverse transcription-PCR, alkaline phosphatase (ALP) activity was assayed and alizarin red S and von Kossa staining were done. Cell viability and apoptosis were also assayed by 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide, a tetrazole (MTT) and flow cytometry, respectively. Results: The osteoblastic differentiation of ADSC as demonstrated by ALP activity was less than that of BMSC. The amount of matrix mineralization has shown by alizar ... Source: www.ncbi.nlm.nih.gov --- 2 days ago
Related Articles Mixing conditions for cell scaffolds affect the Bone formation induced by Bone engineering with human Bone Marrow stromal cells, beta-tricalcium phosphate granules, and rhBMP-2. J Biomed Mater Res A. 2008 Sep 2; Authors: Uchida M, Agata H, Sagara H, Shinohara Y, Kagami H, Asahina I Bone regenerative medicine via tissue engineering is expected to be an alternative treatment for conventional autogenous Bone graft, as it is less invasive. One of the best triads for Bone engineering is Bone Marrow stromal cells, calcium phosphate ceramics, and Bone morphogenetic protein (BMP). However, the optimal mixing conditions for BMP-induced osteoblasts and ceramic granules remain unclear. Therefore, we investigated the effect of the mixing conditions for cell scaffolds on the Bone-forming potential. The cells were mixed with beta-tricalcium phosphate (beta-TCP) granules followed by osteoblast induction with recombinant human BMP-2 (rhBMP-2) (first mixture), or were first induced with rhBMP-2 on plastic dishes and then mixed with the beta-TCP granules (last mixture) just prior to the operation. Both the first and last mixtures were transplanted into nude mice subcutaneously, with the amount of Bone formation analyzed histomorphometrically. In addition, cell numbers and alkaline phosphatase (ALP) activity before transplantation was determined in both the mixtures. In vitro analyses revealed that cell numbers were greater in the last m ... Source: www.ncbi.nlm.nih.gov --- 2 days ago
Related Articles Bone Marrow-derived mesenchymal stem cell transplantation does not improve quality of muscle reinnervation or recovery of motor function after facial nerve transection in rats. Biol Chem. 2008 Jul;389(7):873-88 Authors: Grosheva M, Guntinas-Lichius O, Arnhold S, Skouras E, Kuerten S, Streppel M, Angelova SK, Wewetzer K, Radtke C, Dunlop SA, Angelov DN Recently, we devised and validated a novel strategy in rats to improve the outcome of facial nerve reconstruction by daily manual stimulation of the target muscles. The treatment resulted in full recovery of facial movements (whisking), which was achieved by reducing the proportion of pathologically polyinnervated motor endplates. Here, we posed whether manual stimulation could also be beneficial after a surgical procedure potentially useful for treatment of large peripheral nerve defects, i.e., entubulation of the transected facial nerve in a conduit filled with suspension of isogeneic Bone Marrow-derived mesenchymal stem cells (BM-MSCs) in collagen. Compared to control treatment with collagen only, entubulation with BM-MSCs failed to decrease the extent of collateral axonal branching at the lesion site and did not improve functional recovery. Post-operative manual stimulation of vibrissal muscles also failed to promote a better recovery following entubulation with BM-MSCs. We suggest that BM-MSCs promote excessive trophic support for regenerating axons which, in turn, r ... Source: www.ncbi.nlm.nih.gov --- 3 days ago
Related Articles Bone-Marrow relapse in paediatric acute lymphoblastic leukaemia. Lancet Oncol. 2008 Sep;9(9):873-83 Authors: Bailey LC, Lange BJ, Rheingold SR, Bunin NJ Marrow relapse is the major obstacle to cure for 10-15% of young patients with acute lymphoblastic leukaemia (ALL). Recent investigations into the biology of minimal residual disease indicate that many early relapses derive from residual cells present at first diagnosis, but some late relapses might represent new mutations in leukaemic cells not eliminated by conventional therapy. Treatment of Marrow relapse involves higher doses and more intensive schedules of the drugs used for initial therapy with or without haemopoietic stem cell transplantation. In most reports, transplantation is better than continuation chemotherapy in early Marrow relapse, but its role in later relapse is less clear. Current therapy cures 10% of patients with early Marrow relapses and 50% of those with late relapses, but outcomes have changed little in the past two decades. Understanding the molecular biology of ALL underlies development of improved risk stratification and new therapies. Although better drugs are needed, introduction of new agents into clinical trials in paediatric disease has been difficult. Innovative trial designs and use of valid surrogate endpoints may expedite this process. PMID: 18760243 [PubMed - in process] ... Source: www.ncbi.nlm.nih.gov --- 1 day ago
Related Articles Estrogen action on Bone Marrow osteoclast lineage cells of postmenopausal women in vivo. Osteoporos Int. 2008 Sep 4; Authors: Clowes JA, Eghbali-Fatourechi GZ, McCready L, Oursler MJ, Khosla S, Riggs BL In Bone Marrow aspirates from postmenopausal women, systemic estrogen treatment decreased differentiation of mononuclear progenitor cells toward a more mature osteoclast phenotype. This was not associated with changes in surface receptor for proresorptive cytokines. INTRODUCTION: Although mechanisms by which estrogen (E) decreases Bone resorption have been extensively studied in rodents, little information is available in humans. METHODS: In Bone Marrow aspirates from 34 early postmenopausal women randomly assigned to receive 4 weeks of treatment (100 mug/day of transdermal 17beta-estradiol) or no treatment, we assessed osteoclast differentiation and surface receptors using flow cytometry with fluorescent-labeled specific antibodies. RESULTS: E treatment decreased (P < 0.05) the proportion of Bone Marrow mononuclear cells (BMMNCs) expressing the calcitonin receptor (CTR), a late osteoclast phenotype marker. There was an increase in c-Fms concentration in osteoclast lineage cells (P < 0.05) and in the proportion of BMMNCs expressing TNFR2 (P < 0.05), but there were no significant effects on other surface receptors for proresorptive factors (RANK, TNFR1, TREM2, or OSCAR). Changes in serum CTx and TRAP 5b, markers for Bone ... Source: www.ncbi.nlm.nih.gov --- 1 day ago
Related Articles Bone Marrow microenvironment controls the in vivo differentiation of murine dendritic cells into osteoclasts. Blood. 2008 Sep 2; Authors: Wakkach A, Mansour A, Dacquin R, Coste E, Jurdic P, Carle GF, Blin-Wakkach C Finding that activated T cells control osteoclast (OCL) differentiation has revealed the importance of the interactions between immune and Bone cells. Dendritic cells (DCs) are responsible for T cell activation and share common precursors with OCLs. Here, we show that DCs participate in Bone resorption more directly than simply through T cell activation. We show that among the splenic DC subsets, the conventional DCs (cDCs) have the higher osteoclastogenic potential in vitro. We demonstrate that cDCs differentiate into functional OCLs in vivo when injected into osteopetrotic oc/oc mice defective in OCL resorptive function. Moreover, this differentiation involves the presence of activated CD4(+) T cells controlling a high RANK-L expression by Bone Marrow stromal cells. Our results open new insights in the differentiation of OCLs and DCs and offer new basis for analyzing the relations between Bone and immune systems. PMID: 18768394 [PubMed - as supplied by publisher] ... Source: www.moreover.com --- 17 days ago
Adrian Sudbury received a Bone Marrow transplant that gave him valuable time with friends and family Photo: AP Huddersfield Daily Examiner reporter Adrian Sudbury, 27, passed away with his family beside him at their home in Nottinghamshire, the paper ... Source: www.medicinenet.com --- 10 days ago
Title: Bone Marrow Treatment Approved for Rare Bleeding Disorder Category: Health News Created: 8/23/2008 2:00:00 AM Last Editorial Review: 8/25/2008 ... Source: blog.sheknows.com --- 18 days ago
WHAT: SheKnows (http://www.SheKnows.com) partners with DKMS (dkmsamericas.org), the largest Bone Marrow donor organization, and Save Giovanni’s Friends (helpgiovanniguglielmo.org) to promote awareness of Bone Marrow diseases and pledges to add 50,000 donors to International Bone Marrow Registry by 2009. WHEN: Feature launches live on site August 1, 2008 WHERE: http://www.SheKnows.com/Bone-Marrow WHO: Dr. Jordan Orange, [...] ... Source: www.physorg.com --- 2 days ago
Dogs suffering from lymphoma will be able to receive the same type of medical treatment as their human counterparts, as North Carolina State University becomes the first university in the nation to offer canine Bone Marrow transplants in a clinical setting. ... Source: dogblog.dogster.com --- 4 hours ago
Recently Dogster and the Morris Animal Foundation joined forces on a fundraising campaign to fight canine cancer. Since this devastating disease is so prevalent, killing 1 in 4 dogs, it is imperative to keep raising money for canine cancer research. Hopefully, eventually changing this statistic. I’m always looking for relevant articles on canine cancer research and [...] ... Source: www.newsobserver.com --- 3 days ago
N.C. State University is becoming the first university in the country to offer Bone Marrow transplants for dogs with lymphoma. ... Find more results for Bone Marrow on RSSMicro.com |
Copyright © 2008 RSSMicro.com
Health Newstrack FDA Approves Amgen's Nplate Bone Marrow Stimulant eFluxMedia - 3 hours ago By Alice Turner Following the recommendation of its expert panel back in March, the Food and Drug Administration approved Amgen Inc's drug Nplate for treating a rare clotting disorder that can cause dangerous bleeding. FDA approves Amgen's blood platelet booster Reuters Bone Marrow Treatment Approved for Rare Bleeding Disorder Washington Post Wall Street Journal - Bloomberg - MarketWatch - TMCnet all 64 news articles ...